Literature DB >> 19153164

Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.

Natacha Levi1, Sylvie Bastuji-Garin, Maja Mockenhaupt, Jean-Claude Roujeau, Antoine Flahault, Judith P Kelly, Elvira Martin, David W Kaufman, Patrick Maison.   

Abstract

OBJECTIVE: The aim of this study was to determine the relation of medications to the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in children <15 years of age.
METHODS: We conducted a pooled analysis by using data from 2 multicenter international case-control studies: the severe cutaneous adverse reaction (SCAR) study and the multinational severe cutaneous adverse reaction (EuroSCAR) study conducted in France, Germany, Italy, Portugal, the Netherlands, Austria, and Israel. We selected case subjects aged <15 years, hospitalized for Stevens-Johnson syndrome, Stevens-Johnson syndrome/toxic epidermal necrolysis-overlap, or toxic epidermal necrolysis, and age-, gender-, and country-matched hospital controls. Pooled crude odds ratios were estimated and adjusted for confounding by multivariate methods when numbers permitted.
RESULTS: Our study included 80 cases and 216 matched controls. Antiinfective sulfonamides, phenobarbital, carbamazepine, and lamotrigine were strongly associated with the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Significant associations were highlighted in univariate analysis for valproic acid and nonsteroidal antiinflammatory drugs as a group and for acetaminophen (paracetamol) in multivariate analysis.
CONCLUSIONS: We confirmed 4 previously highly suspected drug risk factors for Stevens-Johnson syndrome/toxic epidermal necrolysis in children: antiinfective sulfonamides, phenobarbital, carbamazepine, and lamotrigine. Among more unexpected risk factors, we suspect that acetaminophen (paracetamol) use increases the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Entities:  

Mesh:

Year:  2009        PMID: 19153164     DOI: 10.1542/peds.2008-1923

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  48 in total

1.  A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

Authors:  James W Antoon; Jennifer L Goldman; Samir S Shah; Brian Lee
Journal:  J Allergy Clin Immunol Pract       Date:  2018-05-30

Review 2.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

3.  Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric P Borrelli; Erica Y Lee; Andrew M Descoteaux; Stephen J Kogut; Aisling R Caffrey
Journal:  Epilepsia       Date:  2018-11-05       Impact factor: 5.864

Review 4.  [Dermatological conditions requiring intensive care].

Authors:  C Marks; R Marks
Journal:  Hautarzt       Date:  2012-09       Impact factor: 0.751

5.  Intravenous immunoglobulin in the treatment of vancomycin-induced toxic epidermal necrolysis.

Authors:  Mohamed A El-Naggari; Hashim Javad; Alexander P Chacko; Anas A Abdelmogheth
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

Review 6.  Toxic epidermal necrolysis in a neonate receiving fluconazole.

Authors:  S Islam; M Singer; J A Kulhanjian
Journal:  J Perinatol       Date:  2014-10       Impact factor: 2.521

7.  The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.

Authors:  Matthew F Daley; Christina L Clarke; Jason M Glanz; Stanley Xu; Simon J Hambidge; James G Donahue; James D Nordin; Nicola P Klein; Steven J Jacobsen; Allison L Naleway; Michael L Jackson; Grace Lee; Jonathan Duffy; Eric Weintraub
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-11-17       Impact factor: 2.890

8.  Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.

Authors:  Xiaohai Li; Theodore M Kamenecka; Michael D Cameron
Journal:  Drug Metab Dispos       Date:  2010-04-09       Impact factor: 3.922

9.  Update on the management of antibiotic allergy.

Authors:  Bernard Yu-Hor Thong
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 10.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.